title: Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
abstract: In an attempt to develop a safer pertussis vaccine, we successfully purified 3 pertussis protective antigens-pertussis toxin, filamentous hemagglutinin, and a 69-kDa outer membrane protein (also named pertactin), from Bordetella pertussis strain ATCC 9340. The toxicity of pertussis toxin could be effectively reduced by the treatment with formaldehyde 0.07% while preserving of a high degree of immunogenicity. By mixing purified pertussis antigens with diphtheria and tetanus toxoids (DT), we have formulated a DT acellular pertussis (DTaP) vaccine. Toxicity studies on body-weight gain in mouse, histamine sensitization, lymphocyte promoting, and Chinese hamster ovary cell clustering tests suggested that this DTaP vaccine is safer than a whole cell vaccine produced in France (DTP[F]). The formulated vaccine elicited high levels of anti-pertussis toxin antibodies in both mice and monkeys. In mice, a 2-fold neutralization of anti-pertussis toxin antibodies was produced by DTaP compared with DTP(F) vaccine and an acellular vaccine manufactured in Japan (DTaP[J]). More importantly, in intracerebral challenge assay in mouse, this vaccine also provided a better protection than DTaP(J).
authors.affiliation: Vaccine Development Center, Taipei, Taiwan, ROC.
authors.forename: G C
authors.initials: GC
authors.lastname: Sheu
authors.forename: Y Y
authors.initials: YY
authors.lastname: Wo
authors.forename: S M
authors.initials: SM
authors.lastname: Yao
authors.forename: F Y
authors.initials: FY
authors.lastname: Chou
authors.forename: T C
authors.initials: TC
authors.lastname: Hsu
authors.forename: C L
authors.initials: CL
authors.lastname: Ju
authors.forename: Y
authors.initials: Y
authors.lastname: Cheng
authors.forename: S N
authors.initials: SN
authors.lastname: Chang
authors.forename: C H
authors.initials: CH
authors.lastname: Lu
mesh_terms: D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry; D001886:Bordetella pertussis / Q000737:chemistry; D004167:Diphtheria Toxin / Q000737:chemistry / Q000633:toxicity*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000276:immunology*; D006388:Hemagglutinins / Q000737:chemistry; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000737:chemistry; D013744:Tetanus Toxin / Q000737:chemistry / Q000633:toxicity*; D018675:Toxicity Tests; D022282:Vaccines, Acellular / Q000009:adverse effects* / Q000627:therapeutic use*; D010566:Virulence Factors, Bordetella / Q000737:chemistry / Q000302:isolation & purification
chemical_list: D001425:Bacterial Outer Membrane Proteins; D004167:Diphtheria Toxin; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D013744:Tetanus Toxin; D022282:Vaccines, Acellular; D010566:Virulence Factors, Bordetella; C068929:pertactin; D037342:Pertussis Toxin